| Authors | Karl-Anton Kreuzer, Richard R Furman, Stephan Stilgenbauer, Ronald L Dubowy, Yeonhee Kim, Veerendra Munugalavadla, Esther Lilienweiss, Hans Christian Reinhardt, Paula Cramer, Barbara Eichhorst, Peter Hillmen, Susan M O'Brien, Andrew R Pettitt, Michael Hallek |
| Journal | Leukemia
(Leukemia)
Vol. 34
Issue 1
Pg. 296-300
(01 2020)
ISSN: 1476-5551 [Electronic] England |
| PMID | 31427720
(Publication Type: Clinical Trial, Phase III, Letter, Multicenter Study, Randomized Controlled Trial)
|
| Chemical References |
- Purines
- Quinazolinones
- Rituximab
- idelalisib
|
| Topics |
- Abnormal Karyotype
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, genetics, mortality)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Progression-Free Survival
- Purines
(therapeutic use)
- Quinazolinones
(therapeutic use)
- Rituximab
(therapeutic use)
- Treatment Outcome
|
